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ABSTRACT
Background: Contrast-induced acute kidney injury (CIAKI) following coronary angiography is
frequently observed in the general population. End-stage liver disease (ESLD) patients are at
a particularly increased risk for development of CIAKI following coronary angiography due to
preexisting renal hypoperfusion.
Methods: We performed a retrospective study of 544 consecutive cardiac catheterizations in
ESLD patients from December 2003 to May 2013 to calculate the incidence of CIAKI post-
coronary angiography and to identify risk factors for CIAKI. CIAKI was defined as a serum
creatinine increase of either ≥ 25% or ≥ 0.5 mg/dL from baseline within 72 hours.
Multivariable and Cox regression analysis was performed for development of CIAKI and all-
cause mortality, respectively.
Results: Overall, 179 cases of coronary angiography were included in the final analysis. CIAKI
occurred in 23% of patients. All-cause mortality was 52% in the CIAKI group and 37% in the
non-CIAKI group, with a mean follow-up of 2.2 ± 3.8 years. Multivariable analysis identified
intensive care unit admission (OR 2.72, CI 1.05–7.01, p < 0.05) and baseline estimated
glomerular filtration rate (OR 1.02, CI 1.002–1.035, p < 0.05) as independent predictors of
CIAKI. Cox regression analysis identified pre-angiography beta-blocker use (HR 2.13, CI
1.04–4.38, p < 0.05), international normalized ratio (HR 1.37, CI 1.05–1.78, p < 0.05) and
Mehran risk score (HR 1.13, CI 1.02–1.25, p < 0.05) as independent predictors of all-cause
mortality.
Conclusions: CIAKI in ESLD patients undergoing coronary angiography occurs at a moderately
elevated rate when compared to the general population.
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1. Introduction
Contrast-induced acute kidney injury (CIAKI) fol-
lowing coronary angiography is a frequent complica-
tion, with incidence rates as high as 55% [1]. The
development of CIAKI following coronary angiogra-
phy is an independent predictor of in-hospital mor-
tality in chronic kidney disease (CKD) patients and
long-term mortality in non-CKD patients [2]. Of
particular concern is the development of CIAKI fol-
lowing coronary angiography in end-stage liver dis-
ease (ESLD) patients, as this patient population has
an increased risk of acute kidney injury (AKI) due to
renal hypoperfusion in the setting of splanchnic vaso-
dilation and systemic vasoconstriction [3].
The incidence of AKI in hospitalized ESLD patients
is as high as 70% [4], with mortality rates up to 63% at
1 year [5]. A small prospective study of ESLD patients
undergoing abdominal computed tomography scans
with contrast media showed no correlation between
contrast administration and subsequent development
of AKI [6]. However, a retrospective cohort study eval-
uating the incidence of CIAKI in ESLD patients under-
going contrast computed tomography reported an
incidence of 25% [7]. The hemodynamic abnormalities
that are common to ESLD patients make predicting
CIAKI difficult.
To our knowledge, the incidence of CIAKI in ESLD
patients undergoing coronary angiography has not
been previously evaluated. Therefore, this study was
performed with the aim of reporting the incidence of
CIAKI following coronary angiography in ESLD
patients and to identify risk factors for the development
of CIAKI. In addition, we studied all-cause mortality
and risk factors for death in the entire cohort of ESLD
patients undergoing coronary angiography.
2. Subjects and methods
2.1. Study design and participants
This study was conducted at a large, academic, tertiary
care center, in which we performed a retrospective
review of 544 consecutive cardiac catheterizations in
ESLD patients from December 2003 to May 2013.
ESLD was defined as clinical findings consistent with
cirrhosis, in addition to either (1) liver biopsy results
with histologic evidence of regenerative nodules
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surrounded by fibrous bands or (2) radiologic evidence
of inhomogeneous hepatic texture, enlarged caudate
lobe, splenomegaly, or splanchnic collateral veins [8].
Of the 544 cardiac catheterizations that were per-
formed, 365 were excluded from subsequent analysis
due to pre-procedure dialysis, lack of contrast use dur-
ing catheterization, or absence of post-angiography
serum creatinine (SCr) data within 72 hours. All 179
cases of coronary angiography included in the final
analysis had at least 1 value for SCr before and 1 value
within 72 hours after the procedure. Cox survival ana-
lysis of all-cause mortality was based on a sample size of
135 unique patients, as only the first encounter was used
for patients with multiple encounters. Two non-ionic,
iso-osmolar contrast media (ioversol and iopamidol)
were used in the cardiac catheterization laboratory at
the time of this study. Participants were followed for up
to 38 ± 31 months post-coronary angiography until the
study end date (13 February 2014) or death. The pro-
tocol was approved by Henry Ford Hospital’s
Institutional Review Board.
2.2. Study variables
CIAKI was defined as a SCr increase of either ≥25% or
≥0.5 mg/dL from baseline within 72 hours, with the
highest SCr within 72 hours being used to determine
whether CIAKI occurred [9]. The most recent SCr
within a 3-month period before contrast exposure was
defined as the baseline SCr and used to calculate the
baseline estimated glomerular filtration rate (eGFR).
eGFR was determined based on the 4 variable
Modification of Diet in Renal Disease (MDRD) Study
equation [10]. Henry Ford Hospital Laboratory began
using isotope dilution mass spectrometry for SCr deter-
mination in 2012, so the MDRD equation used for our
eGFR calculations was adjusted appropriately for values
of SCr obtained after that date [11]. Mortality was
confirmed by public documents available via the
Social Security Death Index. In addition to demo-
graphic characteristics, data were collected on variables
included in the Mehran risk score [1], Model for End-
Stage Liver Disease score [12], and pre-angiography
medications. Comorbidity was identified by physician
review of electronic medical records pertaining to the
eligible patients.
2.3. Study outcomes
The primary outcomes were the incidence of CIAKI
following coronary angiography in ESLD patients and
the risk factors for the development of CIAKI.
Secondary outcomes included all-cause mortality
and risk factors for all-cause mortality in all ESLD
patients who underwent coronary angiography.
2.4. Statistical analysis
The incidence of CIAKI was calculated by counting the
number of patients who developed CIAKI from
December 2003 to May 2013 divided by the total num-
ber of patients who received coronary angiography
during that time. Univariable analysis of risk factors
was done by comparing the 2 main study groups
(CIAKI and non-CIAKI) using 2-sample t-tests for
normally distributed numeric variables, Wilcoxon
rank sum tests for non-parametric distributed numeric
variables, chi-square tests for non-sparse categorical
variables, and Fisher exact tests for sparse categorical
variables. Multivariable logistic regression analysis was
used to identify independent risk factors for CIAKI with
group comparisons (p < 0.2) (New York Heart
Association congestive heart failure class III/IV, intra-
aortic balloon pump use, intensive care unit (ICU)
admission, inotrope use, mechanical ventilation,
Mehran risk score, baseline eGFR, international nor-
malized ratio (INR), and angiotensin-converting
enzyme inhibitor and non-steroidal anti-inflammatory
medication use). In addition, multivariable Cox regres-
sion analysis was used to evaluate the same risk factors
as predictors of all-cause mortality over the complete
follow-up period. P-values <0.05 were considered sta-
tistically significant.
3. Results
Of the 544 cardiac catheterizations that were performed
on ESLD patients from December 2003 to May 2013,
179 were analyzed after exclusion of those cardiac
catheterizations that did notmeet inclusion criteria. All-
cause mortality analysis was based on a sample size of
135 unique patients, as only the first encounter was used
for patients with multiple encounters. Baseline charac-
teristics of the CIAKI and non-CIAKI groups are
reported in Table 1. The 2 cohorts were similar with
regard to age, sex, race, and body mass index. In both
groups, nearly two-thirds of the patients were male.
Both groups had similar rates of diabetes, smoking,
and CKD. New York Heart Association class III/IV
congestive heart failure was present in 41.5% of patients
in the CIAKI group versus 26.8% in the non-CIAKI
group. Acute coronary syndrome as an indication for
coronary angiography was present in 46% of the CIAKI
group and 40% of the non-CIAKI group. CIAKI
occurred in 22.9% of ESLD patients following coronary
angiography. All-cause mortality was 37% in the CIAKI
group and 52% in the non-CIAKI group, with a mean
follow-up of 2.2 ± 3.8 years (Figure 1). When categor-
ized by the use of beta-blockers prior to coronary
angiography, all-cause mortality was 74% in those
with and 26% in those without pre-angiography beta-
blockers (Figure 1). In comparing short- and long-term
creatinine trends between the CIAKI and non-CIAKI
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group, both groups had similar baseline SCr values, but
the peak SCr within 72 hours and 1 year was nearly 80%
and 20% greater in the CIAKI cohort, respectively
(Figure 2).
3.1. Independent predictors of CIAKI
Univariable analysis for risk of CIAKI detected statisti-
cally significant differences with the use of intra-aortic
balloon pumps, inotropes, and mechanical ventilation,
as well as with ICU admission. Multivariable logistic
regression analysis for risk of CIAKI showed that ICU
admission (odds ratio [OR] 2.78, p < 0.05) and baseline
eGFR (OR 1.019, p < 0.05) were statistically significant
risk factors (Table 2). A baseline eGFR threshold of
93 mL/min/1.73 m2 was found to have the strongest
association with the development of CIAKI. No differ-
ences were found with regard to contrast volume, con-
trast ratio [13,14], or contrast-to-eGFR ratio [15].
3.2. Independent predictors of all-cause
mortality
Multivariable Cox regression analysis for risk of
death revealed that pre-coronary angiography beta
blocker use (hazard ratio [HR] 2.13, p < 0.05), INR
(HR 1.37, p < 0.05) and the Mehran risk score (HR
1.13, p < 0.05) predicted all-cause mortality at a mean
follow-up of 2.2 ± 3.8 years (Table 2). An INR of 1.3
and a Mehran risk score of 6 were found to have the
strongest association with all-cause mortality. CIAKI
conferred a trend toward increased mortality (HR
1.78, p = 0.08).
4. Discussion
To our knowledge, this is the first study to evaluate
the incidence of CIAKI in ESLD patients who have
undergone coronary angiography. The cohort of sub-
jects analyzed were all hospitalized patients with
ESLD, a disease state that commonly compromises
kidney function due to decreased renal perfusion
[16]. Based on observational data, the development
of AKI in hospitalized patients with ESLD has been
associated with poor prognosis [17]. Our results sug-
gest that the incidence of CIAKI in ESLD patients
following coronary angiography is elevated in com-
parison to the general inpatient population, with ICU
admission and baseline eGFR < 93 mL/min/1.73 m2
as independent predictors of developing CIAKI.
The pathophysiology of CIAKI in patients with
ESLD is not well studied, but the unique hemody-
namic compromise in these patients likely plays
a significant role. The prevailing theory of CIAKI
involves (1) toxic ischemic injury to the renal tubules
by reactive oxygen species and (2) afferent arteriolar
vasoconstriction caused by decreased nitric oxide
production and decreased prostacyclin activity [3].
The risk of decreased afferent arteriolar perfusion is
likely exaggerated in ESLD patients due to decreased
systemic vascular resistance secondary to portal
hypertension, which subsequently leads to increased
nitric oxide generation within the splanchnic system
and increased endogenous cannabinoid production
[5]. In addition, ESLD patients have concomitant
vasoconstrictor activation due to increased sympa-
thetic nervous system activity and renin-angiotensin-
aldosterone axis activation, both of which further
compromise renal artery perfusion [5].
One retrospective study evaluated ESLD patients
who underwent computed tomography scans with
intravenous contrast and found the incidence of
Table 1. Baseline characteristics of the ESLD cohorts.
Non-CIAKI
group
(n = 138)
CIAKI group
(n = 41)
Age (years) 60.3 ± 9.0 59.1 ± 10.1
Female gender 42 (30.4%) 11 (26.8%)
Caucasian race 92 (66.7%) 26 (63.4%)
Body mass index (kg/m2) 30.3 ± 6.8 30.0 ± 6.5
Chronic conditions
Hypertension 110 (79.7%) 30 (73.2%)
Diabetes mellitus 67 (48.6%) 18 (43.9%)
Hemoglobin A1c (%) 7.6 ± 2.0 7.5 ± 1.9
Chronic kidney disease 45 (32.6%) 11 (28.2%)
CHF (NYHA class III or IV) 37 (26.8%) 17 (41.5%)
Smoking history 75 (54.3%) 25 (61.0%)
Pre-angiography systolic BP (mm Hg) 129.6 ± 30.5 131.0 ± 34.1
Pre-angiography diastolic BP (mm Hg) 67.6 ± 13.5 69.2 ± 15.7
Pre-angiography laboratory
values
Blood urea nitrogen (mg/dL) 20.6 ± 12.0 21.8 ± 13.7
Serum creatinine (mg/dL) 1.2 ± 0.6 1.2 ± 0.6
Baseline eGFR (mL/min/1.73 m2) 70.3 ± 24.9 77.8 ± 31.4
International normalized ratio 1.3 ± 0.9 1.4 ± 0.5
Bilirubin (mg/dL) 1.2 ± 1.2 2.2 ± 4.6
Hematocrit (%) 35.4 ± 6.1 34.8 ± 6.3
Critical indicators
Intra-aortic balloon pump 2 (1.4%) 6 (14.6%)
Intensive care unit admission 22 (15.9%) 18 (43.9%)
Inotropes 3 (2.2%) 6 (14.6%)
Mechanical ventilation 3 (2.2%) 5 (12.2%)
Indications for coronary
angiography
Acute coronary syndrome 55 (39.9%) 19 (46.3%)
Chronic stable angina 46 (33.3%) 9 (22.0%)
New-onset CHF 18 (13.0%) 6 (14.6%)
Pre-operative evaluation 19 (13.8%) 7 (17.1%)
Contrast medium
Contrast volume 114.0 ± 86.5 119.6 ± 125.4
Contrast ratio 0.34 ± 0.38 0.32 ± 0.36
Contrast-to-eGFR ratio 1.9 ± 1.6 2.0 ± 2.2
Risk scores
Mehran risk score 6.2 ± 4.2 8.2 ± 6.1
MELD score 9.6 ± 5.7 11.6 ± 7.7
Periprocedural drugs
Beta-blocker 90 (65.2%) 20 (48.8%)
Diuretic 65 (47.1%) 23 (56.1%)
ACEI/ARB 60 (43.5%) 12 (30.0%)
NSAID 74 (53.6%) 17 (41.5%)
Prophylactic intravenous fluids 52 (37.7%) 12 (29.3%)
Categorical data are reported as frequencies (percentage of group).
Numerical data are reported as mean ± standard deviation. ACEI,
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; BP, blood pressure; CIAKI, contrast-induced acute kidney injury;
CHF, congestive heart failure; eGFR, estimated glomerular filtration rate;
ESLD, end-stage liver disease; MELD, Model for End-Stage Liver Disease;
NSAID, non-steroidal anti-inflammatory drug; NYHA, New York Heart
Association.
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CIAKI to be 25%, similar to what was reported in our
study [7]. Interestingly, this study also found that the
presence of diabetes and the Model for End-Stage
Liver Disease score both lacked predictive power for
the development of CIAKI [7]. In contrast to these
results, a small prospective study did not find an
association between contrast exposure and develop-
ment of CIAKI [6]. This study, however, excluded
patients on diuretic therapy, whereas our study more
closely approximated usual clinical practice, with
nearly half of all subjects prescribed some form of
diuretic prior to coronary angiography. For the inpa-
tient population in general, the incidence of CIAKI
following coronary angiography has been well docu-
mented and has been associated with increased short-
and long-term mortality [2,18,19]. The development
of CIAKI has been linked to the presence of multiple
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Figure 1. All-cause mortality at 1 year and at the end of follow-up based on contrast-induced acute kidney injury (CIAKI) status
and beta-blocker use. Stippled pattern, CIAKI; downward diagonal pattern, non-CIAKI; solid black, beta-blocker; solid white, non-
beta-blocker.
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Figure 2. Creatinine trends before and after coronary angiography based on contrast-induced acute kidney injury (CIAKI) status.
Bars indicate mean and standard deviation for each parameter. Solid black, baseline serum creatinine (SCr); solid white, peak SCr
within 72 hours; stippled pattern, peak SCr within 1 year.
Table 2. Independent predictors of CIAKI and all-cause
mortality for the duration of follow-up.
Parameter P-value Odds Ratio CI
Independent Predictors of CIAKI
ICU admission 0.039 2.72 1.05–7.01
Baseline eGFR (per mL/min/1.73 m2) 0.031 1.02 1.002–1.035
Independent Predictors of All-Cause Mortality
Beta-blocker use 0.039 2.13 1.04–4.38
INR (per 0.1 unit) 0.021 1.37 1.05–1.78
Mehran risk score (per point) 0.016 1.13 1.02–1.25
CIAKI, contrast-induced acute kidney injury; eGFR, estimated glomerular
filtration rate; ICU, intensive care unit; INR, international normalized ratio.
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comorbidities [1,20], but of particular importance in
chronically vasodilated ESLD patients is the finding
that hemodynamic compromise contributes to the
development of CIAKI and increases the risk for all-
cause mortality. CIAKI has been correlated with
increased cardiac mortality [19], and it has been
postulated from animal data that ischemic AKI as
seen in CIAKI may increase subendocardial myocar-
dial ischemia by diminishing coronary vessel reactiv-
ity and inducing a myocardial oxygen supply/demand
mismatch [21]. More recent theories have implicated
a discordance in the activity of endothelial and
smooth muscle progenitor cells in patients with
mild CKD, leading to increased atherosclerosis and
thus cardiovascular mortality [22]. However, this
phenomenon has not been evaluated in subjects
with CIAKI. The individual aspects of these studies
highlight the relevance of identifying risk factors for
the development of CIAKI in ESLD patients under-
going coronary angiography, as they represent
a particularly susceptible cohort of patients for
whom vigilant pre- and post-angiography care may
reduce the risk of CIAKI and all-cause mortality.
Of particular concern is the potential for under-
estimating the incidence of CIAKI in ESLD patients,
as the SCr is commonly diminished in this patient
population due to malnutrition and muscle wasting
[23]. However, the definition of CIAKI as used in this
study, in which proportional increases in SCr were
required, should reduce this underestimation.
The univariable analysis suggested that differences
between ESLD patients with and without CIAKI were,
not surprisingly, indicators of critical illness. After
accounting for potential confounders, multivariable
analysis was able to identify ICU admission and base-
line eGFR as independent predictors for developing
CIAKI. A baseline eGFR threshold of 93 mL/min/
1.73 m2 was found to have the strongest association
with CIAKI, but as previously mentioned, this value
may overestimate the true GFR in the ESLD population
[24,25]. GFR may be overestimated in the ESLD popu-
lation due to protein-calorie malnutrition and muscle
wasting causing decreased creatinine production [26].
In addition, ESLD patients may have impaired liver
synthesis and increased tubular secretion of creatinine,
further contributing to disproportionately decreased
SCr [25,27]. Previous studies have shown that the
MDRD equations may overestimate true GFR in
ESLD patients by 16 ± 22 mL/min/1.73 m2, suggesting
that even lower GFRs may confer an increased risk of
developing CIAKI [24]. More accurate measurements
of GFR by inulin or iothalamate clearance could be
implemented, but most centers would be limited by the
cost, complexity, and lack of availability of these tests.
The Mehran risk score was formulated in 2004 as
a means to quantify the risk of developing CIAKI
after percutaneous coronary intervention [1]. This
risk score was subsequently found to be useful in
predicting mortality in patients with acute myocar-
dial infarction [28,29]. As the Mehran risk score
proved to have an association with development of
CIAKI and mortality in the general population, we
wanted to evaluate its usefulness in the ESLD popu-
lation. The Mehran risk score did not predict the
development of CIAKI in our study, but multivari-
able analysis revealed that a risk score > 6 was an
independent predictor of all-cause mortality. This
finding supports the association of increased mor-
tality with increasing frequency of comorbidities
and hemodynamic instability [18]. Similarly, ele-
vated INR was also predictive of all-cause mortality,
which likely reflects the association of coagulopathy
with worsening liver function. This finding also
supports the well-documented significance of INR
in predicting poor survival in ESLD patients [30].
Pre-angiography use of beta-blockers was also an
independent predictor of all-cause mortality.
A majority (61%) of the patients within the overall
cohort were prescribed beta-blockers prior to cor-
onary angiography. Interestingly, of the patients
who died during follow-up, 75% were administered
periprocedural beta-blockers, nearly 70% of which
were beta-1-selective. Causal relationships cannot
be generally inferred from observational data, but
beta-blocker use may be a surrogate for severity of
liver disease, as ESLD patients with esophageal
varices are commonly prescribed beta-blockers
[31]. Alternatively, beta-blockers may potentiate
renal hypoperfusion during coronary angiography
by decreasing cardiac output [32]. Previous studies
in patients with ESLD and refractory ascites have
demonstrated a deleterious effect of beta-blockers
on mortality [33]. CIAKI showed a trend toward
increased mortality for the duration of follow-up.
Our sample size may have limited our ability to
demonstrate a significant difference between the
CIAKI and non-CIAKI cohorts, therefore stronger
conclusions regarding the relationship between
CIAKI and mortality will likely require further
investigation.
Our study limitations include the retrospective nat-
ure of the analysis, which does not prove a causal
association between contrast exposure and the devel-
opment of CIAKI. However, many previous analyses
including randomized controlled trials, have demon-
strated the association between contrast exposure and
AKI. Additionally, many of our patients were excluded
from the CIAKI analysis due to the absence of post-
angiography SCr data. However, there were no obvious
systematic differences between the ESLD groups with
and without post-angiography SCr measurements;
therefore we are confident the patient sample included
for analysis is representative of the ESLD cohort under-
going coronary angiography.
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5. Conclusion
The incidence of CIAKI in ESLD patients undergoing
coronary angiography in our study was moderately
high at 23%. Risk factors for CIAKI in our population
of ESLD patients were different than those previously
developed for the general population.
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